PolyTherics provides a range of proprietary technologies to enable the development of better biopharmaceuticals. The company’s site-specific conjugation technologies, for example, have the flexibility to conjugate any therapeutic or diagnostic payload (e.g. cytotoxic drug, toxin or radionuclide) to virtually any protein, including antibodies, antibody fragments, or alternative protein scaffolds, and peptides, that bind a specific target. The key benefits of the company’s technologies for production of protein drug conjugates include:

  • More homogeneous product produced so simpler purification and less biological variability
  • Stable link between protein and polymer so conjugate remains intact in vitro and in vivo.

Researchers at PolyTherics have developed a range of heterobifunctional reagents for site-specific conjugation of a variety of payloads to therapeutic proteins and peptides depending on the target of interest.  This toolbox of technologies enables tailoring the linker to the requirements of your protein and payload combination. Incorporating a polymer into the linker brings additional advantages, including:

  • Reduced risk of protein aggregation
  • Improved solubility of the conjugate
  • Easier to monitor conjugation reaction

The London BioScience Innovation Centre
2 Royal College Street
London
NW1 0NH
United Kingdom

MabPlex
 

Web: PolyTherics